Grants

National Institutes of Health/Centers For Disease Control and Prevention $5,000,000 (2000-2008) Principal Investigator: "Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction"
National Institutes of Health $1.07 million [RO1 AI48793-01] (2006-2011) Principal Investigator: "Immunogenetics of Rubella Vaccine Response"
National Institutes of Health NIH/NIAID DAIT BAA 0418 [Contract] [AI40065] $12,000,000 (2004-2009) Principal Investigator "Population Genetics Analysis Program: Immunity to Vaccines/Infections."
National Institutes of Health $100,000 [AI57153] (2003-2005) Principal Investigator Regional Centers of Excellence in Biodefense: "Identification of naturally processed vaccinia peptides to develop a new vaccine."
National Institutes of Health $250,000 [AI57153-03] (2003-2006) Principal Investigator Regional Centers of Excellence in Biodefense: "Emergency Biodefense Response Core."
National Institute of Allergy and Infectious Diseases $887,724 [RO1 AI33144-6] (2008-2013) Principal Investigator: The Immunogenetics of Measles Immunity."
National Institutes of Health $72,250 [RO3 AI053592] (2002-2005) Co-Investigator: "Identification of Measles Class II-Restricted Peptides."

NIAMS [R41 AR052944] (08/01/08-07/31/09) 1.2 calendar months; Principal Investigator: "Detection of biofilm bacteria using GloBac"

The goal of this phase I STTR proposal is to develop the GloBac rapid bacterial detection system and to determine if this novel system can rapidly, sensitively and specifically detect planktonic and biofilm bacteria isolated from patients with prosthetic joint infection.

National Institute of Health [1 R01 AI476536] Lentiviral Genome Processing. Principal Investigator: E. M. Poeschla. Term 05/15/2005-07/31/2009.
National Institute of Health [1 R01 EY14411] Eicosanoid Gene Therapy. Principal Investigator: E. M. Poeschla. Term 3/1/2008-2/29/2012.
National Institute of Health [1 R01 AI77433] LEDGF/p75 and HIV Replication. Principal Investigator: E. M. Poeschla. Term 5/1/2008-4/30/2013.
University of Minnesota & Mayo Partnership for Biotechnology and Medical Genomics grant. Targeting Human LEDGF/p75 and APOBEC3G for Treatment of HIV/AIDS. Principal Investigators: E. M. Poeschla (Mayo) and R. Harris (U of MN). Term 2007-2009.

National Institute of Health [R01 CA100882] 3/1/04-2/28/09; Principal Investigator: "Molecular Pathogenesis of Hepatocellular Carcinoma"
National Institute of Health [R21] Pending; Principal Investigator: "Etiology, Prevention and Treatment of hepatocellular carcinoma"
Bristol-Myers-Squibb Pharmaceuticals 11/1/08-4/30/13. Principle investigator. "The BRIDGE Study to Better Understanding of Outcomes.
MDS Nordion 11/1/08-4/30/09. Principle investigator. "Survival of Patients Receiving Yttrium-90 Microspheres versus Chemoembolization."
KL2 Award Mentor (Principle investigator Dr. Abdirashid Shire). "The Occult Hepatitis B Coinfection with Hepatitis C as a Risk Factor for Hepatocellular Carcinoma in Somali Immigrants: Role of Viral Genetics and Epigenetics and the Immune Response.

National Institute of Health/National Institute of Allergy and Infectious Diseases [R01 AI40384-04AD] 1/1/2007- 2/31/2011; Principal Investigator: "Regulation of HIV-Mediated CD4 T Cell Apoptosis"
National Institute of Health/National Institute of Allergy and Infectious Diseases [R01 AI062261-01] 5/1/2004–4/30/2009; Principal Investigator: "Procaspase 8 Activation by HIV Protease"
Burroughs Wellcome Clinical Scientist Award 7/1/2005-6/30/2010; Principal Investigator: "Novel Antiapoptotic Therapies for Sepsis"
NIDDK [R21 DK 77575-2] 5/1/2007-4/30/2009; Co-Investigator. "Liver Disease Associated with HCV/HIV Coinfection Due to TRAIL"
NCRR [UL1 RR 24150-3] 9/30/2006-6/30/2011; Co-Investigator. "Mayo Clinic Center for Clinical and Translational Research"

NIDDK [R21 DK 77575-2] (2007-2009) Principal Investigator: "Liver Disease Associated with HCV/HIV Coinfection Due to TRAIL"